Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00760370 | Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer | completed | Phase 2 | 60 | Vejle HospitalOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT00388999 |
| Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant |
| completed |
| Phase 1 |
| 46 |
| Enzon Pharmaceuticals, Inc.INDUSTRY |
| 1 |
| Dec 5, 2011 |
| clinicaltrials |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | terminated | Phase 2 | 1 | The Christie NHS Foundation TrustOTHER | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma | completed | N/A | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT01302912 | Lymphoma in the Orbit | unknown | — | 50 | University of ZurichOTHER | 1 | Nov 4, 2011 | clinicaltrials |
| NCT00478777 | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 150 | Celgene CorporationINDUSTRY | 1 | Nov 3, 2011 | clinicaltrials |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00281476 | The Effect of High Dose Simvastatine on Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Vejle HospitalOTHER | 0 | Nov 1, 2011 | clinicaltrials |
| NCT01459887 | Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | completed | Phase 3 | 278 | Shanghai CP Guojian Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 26, 2011 | clinicaltrials |
| NCT00036257 | Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 15 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00073489 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00907348 | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma(REAL07) | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | unknown | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 222 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Oct 10, 2011 | clinicaltrials |
| NCT00530140 | Idiotypic Vaccination for Follicular Lymphoma Patients(FLIDVAX2006) | unknown | Phase 2 | 100 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 6, 2011 | clinicaltrials |
| NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | completed | Phase 1 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 28, 2011 | clinicaltrials |
| NCT01042717 | Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | unknown | N/A | 10 | Shi, Patricia, M.D.INDIV | 1 | Sep 27, 2011 | clinicaltrials |
| NCT01114048 | Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)(KMM-97) | unknown | Phase 2 | 78 | Chonnam National University HospitalOTHER | 1 | Sep 22, 2011 | clinicaltrials |
| NCT01328236 | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia(Bortezomib) | unknown | Phase 2 | 20 | Clinical Service, ChinaINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT00443235 | GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | completed | Phase 3 | 260 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00652041 | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma(TaCyDexVMP7) | completed | Phase 4 | 40 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00504634 | Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2011 | clinicaltrials |
| NCT00934986 | Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia(LLC-NK) | completed | N/A | 70 | Institut Paoli-CalmettesOTHER | 1 | Sep 14, 2011 | clinicaltrials |
| NCT01221103 | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | unknown | Phase 1 / Phase 2 | 50 | Southern Europe New Drug OrganizationOTHER | 1 | Sep 13, 2011 | clinicaltrials |
| NCT00113932 | UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma | completed | Phase 2 | 140 | University of ArkansasOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00118339 | Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma | completed | N/A | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 1, 2011 | clinicaltrials |
| NCT01051115 | Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease(D'ACCORD) | unknown | Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 31, 2011 | clinicaltrials |
| NCT00107614 | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients | terminated | Phase 2 | 12 | University of ArkansasOTHER | 1 | Aug 26, 2011 | clinicaltrials |
| NCT01423032 | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 96 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT01423344 | Clinical Evaluation of the Serum Free Light Chain Analysis | unknown | — | 30 | Charlotte Toftmann HansenOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00569868 | UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma | completed | N/A | 11 | University of ArkansasOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00573391 | Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 | terminated | Phase 3 | 5 | University of ArkansasOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 50 | University of LeipzigOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | completed | Phase 1 | 72 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Aug 4, 2011 | clinicaltrials |
| NCT00263484 | Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma(dtZ) | completed | Phase 2 | 56 | Gleneagles HospitalOTHER | 3 | Jul 21, 2011 | clinicaltrials |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 6 | CancerCare ManitobaOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab | terminated | Phase 2 | 1 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | withdrawn | Phase 2 | 37 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00104104 | A Multiple Myeloma Trial in Patients With Bone Metastases | completed | Phase 4 | 179 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | completed | Phase 2 | 50 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00546780 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse(BMS TIME-1) | completed | Phase 3 | 31 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 28, 2011 | clinicaltrials |
| NCT00846157 | Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients(NKCell) | unknown | Phase 3 | 276 | NKBio Co.Ltd.INDUSTRY | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00142155 | Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia | completed | N/A | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00165295 | Sildenafil Citrate in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00561743 | A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 50 | Janssen-Ortho Inc., CanadaINDUSTRY | 0 | Jun 21, 2011 | clinicaltrials |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | unknown | Phase 1 | 55 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2011source: clinicaltrials